Patient-derived Xenograft Core Facility (PDXCF)

患者来源的异种移植核心设施 (PDXCF)

基本信息

批准号：
10487417
负责人：
Elena Nikolaevna Pugacheva
金额：
$ 17.41万
依托单位：
WEST VIRGINIA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-01 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10487417
关键词：
3-Dimensional Amendment Animal Model Appalachian Region Award Basic Science Biomedical Research Breeding Cancer Model Cancer Patient Centers of Research Excellence Chemoresistance Clinic Clinical Sciences Core Facility Development Environment Extramural Activities Fees Funding Generations Genetic Genetic Variation Goals Human IACUC Immune Immune system Immunotherapy In Vitro Institutes Institutional Review Boards Investments Life Malignant Neoplasms Medical Genetics Mesenchymal Stem Cells Mission Modeling Molecular Mus Patients Pharmaceutical Preparations Population Preclinical Drug Evaluation Procedures Process Productivity Protocols documentation Research Research Infrastructure Research Personnel Research Project Grants Resources Role Sampling Science Services Source Standardization Structure Testing Therapeutic Therapeutic Uses Tissue Banks Tissue Sample Tissue Transplantation Tissues Translating Translational Research Transplantation Tumor-Derived Vendor West Virginia Work Xenograft Model anticancer research cancer health disparity cancer subtypes cancer therapy design human model human tissue improved in vivo evaluation innovation neoplastic cell novel novel therapeutics operation patient derived xenograft model patient population patient response personalized medicine pre-clinical programs quality assurance reconstitution reconstruction success therapeutic evaluation tissue processing tool tumor tumor growth tumor heterogeneity tumor microenvironment tumor xenograft

项目摘要

PROJECT SUMMARY/ABSTRACT The Patient-Derived Xenograft Core Facility (PDXCF) has been recently established and evolved from institutional investments in a breeding colony of immunodeficient (NSG) mice, and the efforts of a cancer research investigator who worked to develop tractable animal models of human tumors. The mission of the PDXCF is to generate cutting edge cancer models that closely resemble heterogeneous human cancers for investigators in the Tumor Microenvironment (TME) Center of Biomedical Research Excellence (CoBRE) as the top priority, and to investigators across the campus to broaden overall impact of this resource. This core will enable enhanced understanding of the TME, facilitate development of novel cancer therapeutics, and improve pre-clinical drug evaluation. Services offered to investigators will be tailored to best fit the needs of research projects in the TME CoBRE. The PDXCF core will provide the following services: 1) transplantation of tissue samples provided by investigators to produce new PDX lines; 2) propagation of established PDX lines; and 3) assistance with submission of IRB and IACUC protocols/amendments. By expanding the research infrastructure, this core facility enables researchers to be more competitive for extramural funding, establish and grow productive research programs, and improve the process of translating basic science to therapeutic application. The proposal describes services provided by the facility along with its management plan, fee structure, prioritization, quality assurance plan, and strategies to sustain the facility over the life of the project and beyond. The Specific Aims of the WVU PDXCF are: 1) to advance the translational research and optimal productivity of the Project Leaders (PLs); 2) to support and develop the core for applications outside the initial TME CoBRE project leaders, and to support the activities of the WVUCI and other WV Institutional Development Award (IDeA) programs that share the overarching goal to reduce cancer health disparities through innovative translational science. Importantly, this core facility will increase the availability of tumor cells from a patient population that is underrepresented in currently available commercial PDX sources.

项目摘要/摘要最近已经建立并从对免疫缺陷（NSG）小鼠的繁殖菌落的机构投资以及癌症的努力研究人员致力于开发可易于的人类肿瘤动物模型。任务 PDXCF将产生尖端的癌症模型，与异质的人类癌症非常相似肿瘤微环境（TME）生物医学研究卓越中心（Cobre）的研究者重中之重，以及整个校园的调查人员，以扩大该资源的整体影响。这个核心将能够增强对TME的了解，促进新型癌症治疗剂的发展并改善临床前药物评估。提供给调查人员的服务将是为最适合研究需求而量身定制的 TME Cobre的项目。 PDXCF核心将提供以下服务：1）组织移植研究人员提供的样品生产新的PDX系列； 2）已建立的PDX线的传播； 3）协助提交IRB和IACUC方案/修正案。通过扩展研究基础设施，该核心设施使研究人员能够在壁外资金，建立和成长方面更具竞争力生产研究计划，并改善将基础科学转化为治疗应用的过程。该提案描述了该设施提供的服务以及其管理计划，费用结构，优先级，质量保证计划以及维持项目及其他地区设施的战略。 WVU PDXCF的具体目的是：1）提高转化研究和最佳生产率项目负责人（PLS）； 2）支持和开发最初TME毛绒之外应用的核心项目负责人，并支持WVUCI和其他WV机构发展奖（IDEA）的活动分享通过创新翻译来减少癌症健康差异的总体目标的计划科学。重要的是，该核心设施将增加患者人群的肿瘤细胞的可用性目前可用的商业PDX来源的代表性不足。